comparemela.com

Latest Breaking News On - Androgen deprivation therapy - Page 8 : comparemela.com

mHSPC: Use of Triplet Therapy

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

Key updatesMetastatic prostate cancer treatmentTriplet therapyProstate cancerMetastatic hormone sensitive prostate cancerHormone sensitive prostate cancerSelecting treatmentSelecting therapyTriple therapyCombination therapyAndrogen deprivation therapyPatient fitnessPatient statusChaarted trialChaarted study

Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

Key updatesMetastatic prostate cancer treatmentHormone sensitive prostate cancerData fromProstate cancerMetastatic hormone sensitive prostate cancerArasens trialArasens studyAndrogen deprivation therapyTriplet therapyTriple therapyCombination therapyAranote trialAranote studyNovel therapy

Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Key updatesMetastatic prostate cancer treatmentProstate cancerMetastatic hormone sensitive prostate cancerHormone sensitive prostate cancerGoals of therapyGoals of treatmentAndrogen deprivation therapyAdt monotherapyCombination therapy

Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Key updatesMetastatic prostate cancer treatmentSelecting therapyProstate cancerMetastatic hormone sensitive prostate cancerHormone sensitive prostate cancerSelecting treatmentDisease volumeChaarted trialChaarted studyAndrogen deprivation therapyTreatment intensificationRadiation therapyDoublet therapyTriplet therapy

Veru Inc : Veru Reports Fiscal 2023 First Quarter Financial Results

Sabizabulin for moderate to severe COVID-19 under review for potential emergency authorization by multiple global regulatory agencies Presented late-breaker oral presentation at IDWeek; sabizabulin treatment

United statesSouth koreaUnited kingdomMitchell steinerSamuel fischHannah gendelSchwierige zeitenEli lillySexual health program updatesOncology program updatesCanada healthEuropean union medicines agencyAustralia therapeutic goods administrationEuropean unionVeru incKorea ministry of food

vimarsana © 2020. All Rights Reserved.